

Synthesis and Antimicrobial Evaluation of Some Chalcone Derivatives of 3-Cinnamoyl-4-hydroxy-6-methyl-2-pyrones

Naziabegum P. Shaikh¹, Shahid F. Shaikh² and S.D. Salunke^{1*}

¹ Research Centre in Chemistry, Rajarshi Shahu Mahavidyalaya, Latur-413512, Maharashtra, India.

² Organic Chemistry Research Laboratory, Yashwant Mahavidyalaya, Nanded-431602, Maharashtra, India.

Abstract

In an effort to develop antimicrobial agents, a series of chalcone derivatives of 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrones were synthesized by base catalyzed condensation of 3-acetyl-4-hydroxy-6-methyl-2-keto-2*H*-pyran (DHA) with different aromatic aldehydes. The synthesized compounds were characterized by means of their IR, and ¹HNMR spectra's. The synthesized compounds were tested for their antibacterial and antifungal activities.

Key words: chalcone, 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrones, dehydroacetic acid, antibacterial, antifungal activity.

1. Introduction

Chalcones are probably the most widely used intermediates for synthesizing various heterocyclic ring systems. Chalcones have shown promising therapeutic efficiency for the management of several diseases due to vast array of structural modification¹. In fact not many structurally diverse compounds exhibit association with such a wide range of pharmacological activities among which cytotoxicity², antitumor³, anti-inflammatory⁴, antiplasmodial⁵, immunosuppression⁶, antioxidant⁷, antibacterial⁸, antifungal⁹, and antiprotozoal are widely cited¹⁰. They also possess antiviral¹¹, antimalarial¹², antiulcerative¹³ and antihyperglycemic¹⁴ activities. Chalcones are used as aldose reductase¹⁵, leukotriene B₄¹⁶ and tyrosinase¹⁷ inhibitors. The presence of reactive α,β-unsaturated keto function in chalcone is found to be responsible for their antimicrobial activity, which may be altered depending on the type and Position of substituent on the aromatic ring. It is not surprising that the chalcones have important feature in many medicinal agents. The synthesis and reactivity of chalcone derivatives has been a topic of research interest for well over a century. Dehydroacetic acid (DHA) also shows promising antifungal¹⁸, antibacterial¹⁹ and antiprotozoal activities²⁰.

The present work deals with the synthesis of chalcones of dehydroacetic acid with different aromatic aldehydes. The synthesized compounds were screened for their antibacterial activity against two gram positive bacteria viz; *Staphylococcus aureus*, *Bacillus subtilis* and two gram negative bacteria viz; *Escherichia coli*, *Salmonella typhi* and the compounds were also used for antifungal studies against *Aspergillus niger*, *Penicillium chrysogenum*, *Fusarium moniliform* and *Aspergillus Flavus* fungal species. The results are summarized in Table I, IIa and IIb for their percentage yield, melting point and confirm whether there is enhancement in antibacterial and antifungal activity due to the keto function is directly bonded to a C=C group.

* Correspondence Info

S. D. Salunke,

Research Centre in Chemistry,

Department of Chemistry and Analytical Chemistry,

Rajarshi Shahu Mahavidyalaya, Latur-413512, India.

Email: salunke_shridhar@rediffmail.com

2. Experimental

2.1. General: Melting points were determined in open capillary and are uncorrected. The IR Spectra were recorded on Shimadzu FT IR / Perkin Elmer RX FT-IR Spectrometer using potassium bromide pellets, ^1H NMR spectra were determined on a Bruker Avance II 400 NMR Spectrometer against TMS as internal standard. Mass spectra were recorded on Water micro mass Q-TOF micro analyzer of S.A.I.F. Panjab University, Chandigarh. Purity of compounds was checked by thin layer chromatographic technique.

2.2. General Procedure for the synthesis of Substituted 3-Cinnamoyl-4-hydroxy-6-methyl-2-pyrones: A mixture of 10 mmol of dehydroacetic acid **1**, 10 mmol of aromatic aldehyde **2** and 8- 10 drops of piperidine as a catalyst was dissolved in 30 ml of chloroform solvent. The reaction mixture was refluxed for a reaction time 8 hours. The reaction mixture was distilled out to remove the azeotropic mixture produced during the reaction. After the complete separation of azeotropic mixture, the remaining chloroform was slowly evaporated to give a solid crude product which was recrystallise from suitable solvent to give the crystals of the corresponding product **3** in good to excellent yield.

2.3. IR, ^1H NMR and Mass Spectral data of 1-(4-hydroxy-6-methyl-2-oxa-2H-pyran-3-yl)-3-phenyl-2-propenone (3a): IR (cm^{-1} , KBr): 3356 (OH), 2940 (CH_3), 1710 (lactone C=O), 1649 (C=O), 1620 (CH=CH). ^1H NMR (CDCl_3 ,d,ppm): 17.7 (s,1H, D_2O exchangeable, OH); 8.21-8.25 (dd,1H $J=9.75$,=CHAr); 7.90-7.94 (dd,1H, $J=9.75$, -C=OCH); 7.68 (m,2H,Ar-H); 7.45 (m,2H,Ar-H); 6.16 (s,1H, C^5H); 2.30 (s,3H, CH_3). Mass m/z: M+ 256, M+1 257.

2.4. IR and ^1H NMR Spectral data of 1-(4-hydroxy-6-methyl-2-oxa-2H-pyran-3-yl)-3-(4-hydroxyphenyl)-2-propenone (3c): IR (cm^{-1} , KBr): 3266 (OH), 1697 (lactone C=O), 1647 (C=O), 1603 (CH=CH). ^1H NMR (CDCl_3 ,d,ppm): 18.1 (s,1H, D_2O exchangeable, OH); 8.20-8.24 (dd,1H, $J=9.75$, =CHAr); 7.95-7.99 (dd,1H, $J=9.85$, -C=OCH); 7.62 (m,2H,Ar-H); 6.89 (m,2H,Ar-H); 5.97 (s,1H, C^5H); 5.55 (s,1H,OH); 2.19 (s,3H, CH_3).

2.5. IR, ^1H NMR and Mass Spectral data of 1-(4-hydroxy-6-methyl-2-oxa-2H-pyran-3-yl)-3-(2-hydroxyphenyl)-2-propenone (3d): IR (cm^{-1} , KBr): 3226 (OH), 1689 (lactone C=O), 1647 (C=O), 1615 (CH=CH). ^1H NMR (CDCl_3 ,d,ppm): 18.1 (s,1H, D_2O exchangeable, OH); 8.20-8.24 (dd,1H,=CHAr); 7.95 (m,1H,Ar-H); 7.63-7.65 (d,1H,C=OCH); 7.02 (m,3H,Ar-H); 5.97 (s,1H, C^5H); 5.55 (s,1H,OH); 2.19 (s,3H, CH_3). Mass m/z: M 272.

2.3. IR and ^1H NMR Spectral data of 1-(4-hydroxy-6-methyl-2-oxa-2H-pyran-3-yl)-3-(4-bromoyphenyl)-2-propenone (3e): IR (cm^{-1} , KBr): 3105 (OH), 1708 (lactone C=O), 1624 (C=O), 1597 (CH=CH). ^1H NMR (DMSO,d,ppm): 8.33-8.37 (dd,1H,=CHAr); 8.30 (d,2H,Ar-H); 7.96-7.97 (d,1H,-C=OCH); 7.91-7.93 (d,2H,Ar-H); 6.18 (s,1H, C^5H); 2.33 (s,3H, CH_3).

3. Result and discussion

The Chalcones of dehydroacetic acid were synthesized by Claisen-Schmith condensation in good to excellent yields (**Scheme 1**). All of the synthesized compounds exhibit antibacterial and antifungal activity. The structures of all the compounds were established from IR and ^1H NMR spectral analysis. The IR spectrum of compounds **3a**, **3d** and **3e** showed a broad band for OH group at 3356 cm^{-1} , 3216 cm^{-1} and 3105 cm^{-1} and sharp and strong band at 1710 cm^{-1} , 1689 cm^{-1} and 1708 cm^{-1} for lactone carbonyl group. Another sharp band observes at 1649 cm^{-1} , 1647 cm^{-1} and 1624 cm^{-1} due to the presence of carbonyl group and at 1620 cm^{-1} , 1615 cm^{-1} and 1597 cm^{-1} for the carban-carban double bond of a,b-unsaturated chalcone system. The ^1H NMR spectra of **3a**, **3d** and **3e** showed a characteristic singlet due to $\text{C}^5\text{-H}$ proton around d 6.16, 5.97 and 6.18 ppm for lactone unit. We also noted the olefinic protons of reactive a,b-unsaturated keto function occurs as doublet around d 7.90-7.94 ($J=9.75$) and 8.21-8.25 ($J=9.75$), d 7.93-7.97 ($J=8.0$) and 8.33-8.37 ($J=8.3$) for **3a** and **3e** (Figure1). A broad singlet around d 17.7 and 18.1 due to D_2O exchangeable OH group of lactone unit.

Scheme 1: Synthesis of chalcone derivatives of 3-Cinnamoyl-4-hydroxy-6-methyl-2-pyrones



Figure 1: ¹HNMR spectrum of 3a

Table 1: Percentage yield and melting points of Substituted 3-Cinnamoyl-4-hydroxy-6-methyl-2-pyrones.

Entry	X	Product	Yield %	M.P. ^o C
1		 3a	69	130-132
2		 3b	74	245-246
3		 3c	81	260-262
4		 3d	65	197-198
5		 3e	68	211-212
6		 3f	71	196-197

3.1. Antimicrobial Activity: The synthesized compounds are screened for their antibacterial activity against two gram positive bacteria viz; *Bacillus subtilis*, *Staphylococcus aureus* and two gram negative bacteria viz; *Escherichia coli*, *Salmonella typhi* by using agar cup method²¹. The agar cup medium was purchased from HI media laboratories Ltd. Mumbai, India. The preparation of nutrient broth, subculture, base layer medium, agar medium and peptone water was done as per standard procedure. The solution of the test compounds were prepared by dissolving 5mg each in 5mL of dimethylsulfoxide at a concentration of 1000 mg/ mL. The cups each of 10 mm in diameter were made by scooping out medium with a sterilized cork borer in a Petri dish which was streaked with the organism. The solutions of each test compound (0.1 mL) were added separately in the cups and petri dishes were subsequently incubated. Penicillin was used as standard / reference drug and Dimethyl Sulphoxide as a control which did not reveal any inhibition. Zone of inhibition produced by each compound was measured in mm. The results of antibacterial studies are given in Table 2a.

The compounds screened for antibacterial activity were also tested for their antifungal activity using potato-dextrose agar (PAD) medium by plate method against *Aspergillus niger*, *Penicillium chrysogenum*, *Fusarium moneliform* and *Aspergillus Flavus*. The PAD medium was purchased from HI media laboratories Ltd. Mumbai, India. The preparation of nutrient broth, subculture, base layer medium, agar medium and peptone water was done as per standard procedure. The solution of the test compounds were prepared by a similar procedure described under the antibacterial activity. Each test compound 5mg each in 5mL of dimethylsulfoxide at a concentration of 1000 mg/ mL was used for screening. A reference / standard Griseofulvin used as -ve standard and dimethylsulfoxide as a control which did not reveal any inhibition. The results of antifungal activities of the screened compounds are given in Table 2b.

4. Conclusion

In conclusion, we have synthesized chalcones from starting material 3-acetyl-4-hydroxy-6-methyl-2-keto-2H-pyran. The newly synthesized chalcone derivatives were fully characterized by spectral analysis. Moreover, we studied the biological importance of synthesized compounds by screening their antimicrobial activity against four fungi [*Aspergillus niger*, *Penicillium chrysogenum*, *Fusarium moneliform* and *Aspergillus Flavus*] and two Gram +ve [*Bacillus subtilis*, *Staphylococcus aureus*] as well as two Gram -ve [*Escherichia coli*, *Salmonella typhi*] bacteria. Compounds **3a** and **3d** shows excellent antibacterial activity against all the test microorganism except *Salmonella typhi*. Compound **3a** was more potent antibacterial than the reference drug showed highest inhibition zone 14 mm against *Escherichia coli* than reference Penicillin 13 mm. Compounds **3c** and **3e** were inactive against all the test microorganism. Compounds **3a**, **3c**, **3d** and **3e** exhibited the high antifungal against all test microorganism except **3c** and **3d** against *Aspergillus niger*, *Penicillium chrysogenum*.

Acknowledgements

The author N.P. Shaikh is thankful to the UGC, New Delhi, for providing Maulana Azad National Fellowship (Junior Research Fellowship) and Principal, Rajarshi Shahu Mahavidhyalaya, Latur for providing all necessary research facilities to carry out this work.

References

1. Nielsen SB, Christensen SF, Cruciani G, Kharazmi A, Antileishmanial chalcones: statistical design, synthesis, and three-dimensional quantitative structure-activity relationship analysis. *J. Med. Chem.* 1998; 41 (24):4819-32.
2. Gudapati V.R., Badrappa N.S., Venkateshappa C.G., Chandrasekara R. Synthesis of (±)Abyssinone I and related compounds: Their anti-oxidant and cytotoxic activities *Eur. J. Med. Chem.* 2009; 44: 2239-2245.
3. Cabrera M., Simoens M., Fatchi G., Lavaggi M.L., Piro G.E., Castellano E.E. Synthetic chalcones, flavanones, and flavones as antitumoral agents: Biological evaluation and structure-activity relationships *Bioorg. Med. Chem.* 2007; 15: 3356-3367.
4. Nowakowska Z. A review of anti-infective and anti-inflammatory chalcones. *Eu. J. Med. Chem.* 2007; 42: 125-137.
5. Jose N.D., Cartiza L., Juan R., Neira G. de. D., Jiri G., Philip J.R. Synthesis of chlorovinyl sulfones as structural analogs of chalcones and their antiplasmodial activities. *Eur. J. Med. Chem.* 44, 2009, 1457-1462.
6. Go M.L., Wax., Liux L., Chalcones: An update on Cytotoxic and Chemo protective properties *Curr. Med. Chem.* 2005; 12: 483-499.
7. Hocine A., Faouzi G., Coco N.K., Dider M.L., Christopher R.M., Jacques H.P. *Medi. Chem. Res.* 2009, 18, 467-476.

8. Hugo P.A., Elzade F.A.S., Franco D.M., Arter S. *J.Biorg.Med.Chem.* 16,2008,9790-9794.
9. Ponnurengam M.S., Thangovelu M.K., Mukesh d. *Chem.Biol.Drug.Des.* 2009,74,68-79.
10. Faisal H., Emma M.,Attar S.,Robyn L., Vaz Z., Amir A. *Eur.J.Medi.Chem.* 2011,465,1897-1905.
11. Jalpa C.T., Jitender B.B., Kullip D.U., Yogesh T.N., Sudhir K.J., Christophe C.P., Erick D.C., Anamik K.S. *Tetrahedron Lett.* 2007,4848,8472-8474.
12. Satish K.A., Nidhi M., Brajesh K., Manish S., Amit B., Lokesh C.M., Virendra K.B. *Med.Chem. Res.* 2009,18,407-420.
13. Gamal El., Din A.A., Abuo-Rahma., Mohamed A.A., Mai AE.M., Hassan H.F.*Biorg.Med.Chem.* 2012,20(1),195-206.
14. Narender T., Dapi R.K. *Tetrahedron Lett.* 48,2007,3177-3180.
15. Soon S.L., Sang H.J., Jun J.K.H.S., Sam R.K. *Chem. Pharm. Bull.* 2000,48(11),1786-1789.
16. Anil M.D., Narshimha P.A., Arvind A.N. Jusan E. *Biorg. Med. Chem.* 1999 7(6),1237-1240.
17. Louise D.C., Alessandra M., Marcela P., Javier V., Marlon N.S.C., Maria E.Z., Andrea V. Ricardo J.N., Rosendo A.Y., Hernan T. *Bioorg. Med. Chem. Lett.* 18,2008,6227-6230.
18. Surya Rao D., Subha Rao B. L., John V. T., Ganorkar M. C. *Nat. Acad. Sci. Lett.* 1, 1978, 402.
19. Surya Rao D., Sadasiva Reddy C., John V. T., Ganorkar M. C. *Curr. Sci.* 49,1980, 511.
20. Schleiffenbaum B., Spertini O., Tedder Thomas F., *J. Cell. Biol.* 119,1992,229. (b) Stanley V. G., Woldesenbet S., Cassandra G., *Poult. Sci.* 75,1996,42.
21. Kumar H., Jain S., *Int. J. Pharm. Sci. Res.* 4(1), 2013, 453-457.